WO2010054470A1 - Composition de perte de poids de potiron et de fruit du rosier - Google Patents

Composition de perte de poids de potiron et de fruit du rosier Download PDF

Info

Publication number
WO2010054470A1
WO2010054470A1 PCT/CA2009/001621 CA2009001621W WO2010054470A1 WO 2010054470 A1 WO2010054470 A1 WO 2010054470A1 CA 2009001621 W CA2009001621 W CA 2009001621W WO 2010054470 A1 WO2010054470 A1 WO 2010054470A1
Authority
WO
WIPO (PCT)
Prior art keywords
composition
rosa canina
cucurbita moschata
astaxanthin
nelumbo nucifera
Prior art date
Application number
PCT/CA2009/001621
Other languages
English (en)
Inventor
Raza Bashir
Megan Thomas
Ken Clement
Original Assignee
Northern Innovations And Formulations Corp.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Northern Innovations And Formulations Corp. filed Critical Northern Innovations And Formulations Corp.
Priority to CA2743266A priority Critical patent/CA2743266A1/fr
Publication of WO2010054470A1 publication Critical patent/WO2010054470A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/42—Cucurbitaceae (Cucumber family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/62—Nymphaeaceae (Water-lily family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
    • A61K36/738—Rosa (rose)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/82—Theaceae (Tea family), e.g. camellia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/87—Vitaceae or Ampelidaceae (Vine or Grape family), e.g. wine grapes, muscadine or peppervine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/60—Sugars; Derivatives thereof
    • A61K8/602—Glycosides, e.g. rutin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9783—Angiosperms [Magnoliophyta]
    • A61K8/9789—Magnoliopsida [dicotyledons]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9783—Angiosperms [Magnoliophyta]
    • A61K8/9794—Liliopsida [monocotyledons]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/06—Preparations for care of the skin for countering cellulitis

Definitions

  • the present invention relates to compositions and methods for maintaining or reducing body weight in mammals. More specifically, the present invention relates to combinations of herbal ingredients for supporting weight loss.
  • the present invention provides a method of maintaining or reducing the body weight of subjects by promoting an increase in lipolysis and promoting a decrease in lipogenesis, in subjects.
  • a method for promoting weight loss comprising administration of a composition comprising Cucurbita moschata and at least one of the group consisting of Rosa canina, Cissus Quadrangularis, NeI urn bo nucifera, Ilex paraguariensis, astaxanthin, Salvia officinalis, Rosmarinus officinalis, Green tea leaf, anhydrous caffeine, Astragalus membranaceus, Alisma plantago aquatica, Catharanthus roseus, Acorus calamus, Euphorbia balsamifera, Jatropha curcas, Origanum majorana, Zea mays, Capsicum frutescens, Urtica dioica and Pueraria thomsonii.
  • the composition ingredients are provided as plant extracts.
  • the composition comprises Rosa canina and Cucurbita moschata, and the Rosa canina comprises trans-tiliroside.
  • a composition comprising Cucurbita moschata and at least one of the group consisting of Rosa canina, Cissus Quadrangularis, Nelumbo nucifera, Ilex paraguariensis, astaxanthin, Salvia officinalis, Rosmarinus officinalis, Green tea leaf, anhydrous caffeine, Astragalus membranaceus, Alisma plantago aquatica, Catharanthus roseus, Acorus calamus, Euphorbia balsamifera, Jatropha curcas, Origanum majorana, Zea mays, Capsicum frutescens, Urtica dioica and Pueraria thomsonii.
  • the composition is a weight loss composition, and may comprise Rosa canina and Cucurbita moschata.
  • the Rosa canina and Cucurbita moschata may be provided as plant extracts.
  • the present invention is directed to methods and compositions for maintaining or reducing body weight. This is achieved by providing compositions, and methods employing said compositions, directed at increasing lipolysis, while substantially simultaneously decreasing lipogenesis.
  • the term "maintaining or reducing body fat” refers to the act or a state of a static amount of body fat or a dynamic state of decreasing body fat. It is herein understood that the amount of body fat is regulated by multiple mechanisms, such as, for example, fat synthesis, fat esterification and fat storage (collectively, herein termed lipogenesis), and fat oxidation, fat breakdown and fat mobilization (collectively, herein termed lipolysis). Furthermore, it is herein understood that the amount of body fat may be maintained or reduced by affecting any mechanism, both directly or indirectly, that regulates the amount of body fat, and that affecting multiple fat regulation mechanisms will have greater efficacy than affecting any single mechanism. It is herein understood that decreasing lipogenesis and/or increasing lipolysis will advantageously maintain or reduce body fat.
  • the term "subject” refers to mammals and non-mammals.
  • Mammals refers to any member of the Mammalia class including, but not limited to, humans; non-human primates such as chimpanzees and other apes and monkey species; farm animals such as cattle, horses, sheep, goats, and swine; domestic animals such as rabbits, dogs, and cats; laboratory animals including rodents, such as rats, mice, and guinea pigs; and the like.
  • non- mammals include, but are not limited to, birds, and the like. In preferred embodiments of the present invention the subjects are human.
  • oral administration refers to acceptable oral dosage forms taken by conventional routes of administration known by one of skill in the art and include, for example, powder beverage mixes, liquid beverages, ready-to-eat bars, soft and hard capsules, liquid capsules, tablets, caplets and dietary gels.
  • the preferred dosage forms of the present invention are caplets and capsules.
  • the dosage form of the nutritional supplement is provided in accordance with customary processing techniques for herbal and nutritional supplements in any of the forms mentioned above.
  • the nutritional supplement set forth in the example embodiment herein disclosed may contain any appropriate number and type of excipients, as is well known in the art.
  • plant extracts refers to whole plant or any portion(s) thereof, fresh or dried, treated by any means as are commonly known to those of skill in the art, to obtain a portion which contains one or more active compounds.
  • Such extracts are typically liquid but may subsequently be provided as a dry powder.
  • the extracts are standardized to some know compound present in the isolated extract. Examples of common extracts methods include aqueous and alcohol extractions.
  • suitable solvents such as methylene dichloride, acetone, ethanol, methanol, methanol/chloroform/water and water.
  • Extracts includes both crude extracts and extracts obtained from more elaborate methods such as solid-phase extraction, solid-phase microextraction, supercritical-fluid extraction, pressurized-liquid extraction, microwave-assisted extraction, and surfactant-mediated extraction.
  • Plant extract as used herein, may also include extracted oils such as those referred to as essential oils.
  • forms of unprocessed, or raw, plants may be used in embodiments of the present invention. Such forms may be whole or part and may be fresh or dried. In preferred embodiments of the present invention, plant extracts are used.
  • the term 'nutritional composition' includes dietary supplements, diet supplements, nutritional supplements, supplemental compositions and supplemental dietary compositions or those similarly envisioned and termed compositions not belonging to the conventional definition of pharmaceutical interventions as is known in the art. Furthermore, 'nutritional compositions' as disclosed herein belong to category of compositions having at least one physiological function when administered to a subject by conventional routes of administration.
  • formulations and nutritional compositions belonging to the present invention may be considered to be nutraceuticals.
  • the term 'nutraceutical' is recognized and used in the art to describe a specific chemical compound or combination of compounds found in, organic matter for example, which may prevent, ameliorate or otherwise confer benefits against an undesirable condition.
  • the term 'nutraceutical' is used to refer any substance that is a food, a part of food, or an extract of food which is suitable for consumption by an individual and providing physiological benefit which may be medical or health-related.
  • the term has been used to refer to a product isolated, extracted or purified from foods or naturally-derived material suitable for consumption by an individual and usually sold in medicinal forms, such as caplets, tablet, hard and soft capsules, and the like, not associated with food.
  • one or more components are processed so as to form fine-milled particles.
  • one or more ingredients of the dietary supplemental are processed by a large-scale milling technique that produces fine particles that have a smaller average particle size.
  • the use of milling techniques, in combination with excipients and polymers, to form fine-milled particles has been shown to improve flow and dispersability, stability, resistance to moisture, bioavailability, and dissolution/release properties.
  • Formulations benefit by containing fine-milled particles for the purpose of providing the one or more ingredients in particle sizes that optimize one or more of: the flow and dispersability, stability, resistance to moisture, bioavailability, and dissolution/release properties of the one or more ingredients in a dietary supplement.
  • PPAR peroxisome proliferator- activated receptor
  • PPAR- ⁇ is predominantly expressed in liver and regulates fatty acid catabolism.
  • PPAR-Y is expressed primarily in adipose tissue and is involved in regulating adipogenesis and fat storage.
  • PPAR- ⁇ is expressed in several tissue types. Activation of PPARs leads to and improved glucose and lipid homeostasis. Specific activation of PPAR- ⁇ results in increased lipid oxidation.
  • PPAR agonists are a class of pharmaceutical intervention aimed at treating several conditions, including obesity. Both selective PPAR- ⁇ agonists and various combination therapies have been shown to be efficacious.
  • LPL Lipoprotein lipase
  • ACO-1 Acyl-CoA oxidase-1
  • CPT-1 carnitine palmitoyltransferases
  • UCPs Uncoupling proteins
  • SREBP-I c Sterol Regulatory Element Binding Proteini c
  • SCD stearoyl-CoA desaturase
  • FOS fatty- acid synthase
  • ACC acetyl-coenzyme A carboxylase
  • Rosa canina L. is a prickly shrub found in Scotland and other parts of Europe. Traditionally the fruit of this plant have been used as diuretic, laxative and for anti-gout purposes. The principal constituent, trans-tiliroside, has been shown to increase the expression of PPAR- ⁇ .
  • PPAR agonist activity including Salvia officinalis (Sage), Rosmarinus officinalis (Rosemary), Astragalus membranaceus, Alisma plantago aquatica, Catharanthus roseus, Acorus calamus, Euphorbia balsamifera, Jatropha curcas, Origanum majorana, Zea mays, Capsicum frutescens, Urtica dioica and Pueraria thomsonii.
  • Embodiments of the present invention comprise at least one compound that increases lipolysis in a subject. It is herein understood that increasing lipolysis in a subject will act to maintain or reduce body fat in the subject.
  • the preferred route of increasing lipolysis is through modulating PPAR activity. It is herein understood that increasing PPAR activity, preferably PPAR- ⁇ activity, will increase lipolysis, thereby acting to decrease body fat.
  • Preferred embodiments of the present invention comprise Rosa canina as a source of compound that increases PPAR activity.
  • the preferred PPAR activity increasing compound is trans-tiliroside.
  • various embodiments of the present invention may include one or more compound that increases the activity of a lipolytic factor other than (or in addition to) PPAR.
  • Astaxanthin is known to increase CPT-1 activity.
  • Nelumbo nucifera is an aquatic plant that has demonstrated activity towards increasing UCP-3 activity.
  • Ilex paraguariensis also known as Yerba mate
  • Yerba mate is a common tree in Southern Brazil, Northeastern Argentina, Paraguay and convinced that may increase UCP2 and UCP3 expression
  • Cucurbita moschata commonly called pumpkin, has displayed anti- obesity effects in mouse models.
  • Oral administration of an extract of Cucurbita moschata decreased the weights of various adipose tissues.
  • the size of the adipocytes and thickness of fat pad in subcutaneous area was also markedly decreased in treated animals.
  • the mRNA level of SREBP-Ic and SCD-1 and FAS were markedly decreased in treated mice, while the mRNA of lipolytic factors PPAR- ⁇ , ACO- 1 , CPT-1 , and UCP-2 were increased. This indicates that oral administration of Cucurbita moschata may suppress body fat accumulation by down-regulating mRNA expression of lipogenic genes and up-regulating the expression of lipolytic genes.
  • any factors controlling or regulating any aspect of fat metabolism may be modulated through dietary interventions such as those of the present invention.
  • interventions may exert said modulations through effecting any biological, chemical or biochemical pathway such as those including but not limited to: DNA replication or amplification, RNA transcription, RNA stability, RNA translation, post-translational modifications such as phosphorylation, ligand binding, and transport, either directly or indirectly. Accordingly, such interventions are supportive of promoting weight loss.
  • the methods and compositions of the present invention are suited for use for individuals wishing to maintain or reduce their body weight at the expense of body fat.
  • the methods and compositions of the present invention may be used in combination with other like-directed ingredients or compositions to maintain or reduce their body weight.
  • Other like-directed ingredients or compositions will be known by those of skill in the art.
  • composition for supporting weight loss in an individual comprising the following ingredients per serving is prepared for consumption as 2 caplets to be consumed twice daily:
  • composition for supporting weight loss in an individual comprising the following ingredients per serving is prepared for consumption as 2 caplets to be consumed twice daily:
  • composition for supporting weight loss in an individual comprising the following ingredients per serving is prepared for consumption as 2 caplets to be consumed twice daily:
  • composition for supporting weight loss in an individual comprising the following ingredients per serving is prepared for consumption as 2 capsules to be consumed twice daily:

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Botany (AREA)
  • Mycology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Birds (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Medical Informatics (AREA)
  • Child & Adolescent Psychology (AREA)
  • Obesity (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

La présente invention concerne des procédés et des compositions pour maintenir ou réduire le poids corporel par administration de compositions visant à augmenter la consommation des graisses et l’activité lipolytique, tout en diminuant simultanément l’activité de stockage de graisses. Les compositions décrites comprennent Cucurbita moschata et au moins l’un de Rosa canina, Cissus Quadrangularis, Nelumbo nucifera, Ilex paraguariensis, l’astaxanthine, Salvia officinalis, Rosmarinus officinalis, des feuilles de thé vert, la caféine anhydre, Astragalus membranaceus, Alisma plantago aquatica, Catharanthus roseus, Acorus calamus, Euphorbia balsamifera, Jatropha curcas, Origanum majorana, Zea mays, Capsicum frutescens, Urtica dioica et Pueraria thomsonii.
PCT/CA2009/001621 2008-11-17 2009-11-16 Composition de perte de poids de potiron et de fruit du rosier WO2010054470A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA2743266A CA2743266A1 (fr) 2008-11-17 2009-11-16 Composition de perte de poids de potiron et de fruit du rosier

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US19948308P 2008-11-17 2008-11-17
US61/199,483 2008-11-17

Publications (1)

Publication Number Publication Date
WO2010054470A1 true WO2010054470A1 (fr) 2010-05-20

Family

ID=42169561

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CA2009/001621 WO2010054470A1 (fr) 2008-11-17 2009-11-16 Composition de perte de poids de potiron et de fruit du rosier

Country Status (2)

Country Link
CA (1) CA2743266A1 (fr)
WO (1) WO2010054470A1 (fr)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2968213A1 (fr) * 2010-12-03 2012-06-08 Oreal Utilisation d'une association amincissante
WO2013122235A1 (fr) * 2012-02-15 2013-08-22 森下仁丹株式会社 Composition destinée à prévenir, améliorer ou traiter le syndrome métabolique
EP2815756A4 (fr) * 2012-02-15 2015-10-14 Morishita Jintan Co Composition destinée à prévenir, améliorer ou traiter le syndrome métabolique
CN107375847A (zh) * 2017-08-14 2017-11-24 青岛康尔高科实业有限公司 一种减肥药物、其制备方法及应用
FR3087339A1 (fr) * 2018-10-22 2020-04-24 Nexira Composition pour traiter le surpoids et/ou l'obesite
US10674746B2 (en) 2015-10-27 2020-06-09 Cytozyme Animal Nutrition, Inc. Animal nutrition compositions and related methods
US11297851B2 (en) 2015-10-27 2022-04-12 Cytozyme Laboratories, Inc. Animal nutrition compositions and related methods

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050003026A1 (en) * 2002-08-14 2005-01-06 Song-Hae Bok Powder or extracts of plant leaves with anti-obesity effects and anti-obesity food comprising them
US6869621B2 (en) * 2002-11-08 2005-03-22 Eromlife Co., Ltd. Diet composition comprising raw foods and dietary fibers
US20080260934A1 (en) * 2005-02-24 2008-10-23 Song Hae Bok Food for Preventing Fatness and Hyperlipemia

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050003026A1 (en) * 2002-08-14 2005-01-06 Song-Hae Bok Powder or extracts of plant leaves with anti-obesity effects and anti-obesity food comprising them
US6869621B2 (en) * 2002-11-08 2005-03-22 Eromlife Co., Ltd. Diet composition comprising raw foods and dietary fibers
US20080260934A1 (en) * 2005-02-24 2008-10-23 Song Hae Bok Food for Preventing Fatness and Hyperlipemia

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2968213A1 (fr) * 2010-12-03 2012-06-08 Oreal Utilisation d'une association amincissante
WO2012072670A3 (fr) * 2010-12-03 2013-07-11 L'oreal Utilisation d'une association d'amaigrissement
WO2013122235A1 (fr) * 2012-02-15 2013-08-22 森下仁丹株式会社 Composition destinée à prévenir, améliorer ou traiter le syndrome métabolique
JP2014177406A (ja) * 2012-02-15 2014-09-25 House Wellness Foods Kk メタボリックシンドロームの予防、改善または治療用組成物
US20150190448A1 (en) * 2012-02-15 2015-07-09 Morishita Jintan Co., Ltd. Composition for prevention, amelioration or treatment of metabolic syndrome
EP2815756A4 (fr) * 2012-02-15 2015-10-14 Morishita Jintan Co Composition destinée à prévenir, améliorer ou traiter le syndrome métabolique
US9669063B2 (en) 2012-02-15 2017-06-06 Morishita Jintan Co., Ltd. Composition for prevention, amelioration or treatment of metabolic syndrome
US10674746B2 (en) 2015-10-27 2020-06-09 Cytozyme Animal Nutrition, Inc. Animal nutrition compositions and related methods
US11297851B2 (en) 2015-10-27 2022-04-12 Cytozyme Laboratories, Inc. Animal nutrition compositions and related methods
CN107375847A (zh) * 2017-08-14 2017-11-24 青岛康尔高科实业有限公司 一种减肥药物、其制备方法及应用
FR3087339A1 (fr) * 2018-10-22 2020-04-24 Nexira Composition pour traiter le surpoids et/ou l'obesite

Also Published As

Publication number Publication date
CA2743266A1 (fr) 2010-05-20

Similar Documents

Publication Publication Date Title
US9345732B2 (en) Agents derived from Holoptelea integrifolia and their compositions for the control of metabolic syndrome and associated diseases
Kao et al. Polyphenolic extract from Hibiscus sabdariffa reduces body fat by inhibiting hepatic lipogenesis and preadipocyte adipogenesis
Tang et al. Polyphenol-rich extract of Nelumbo nucifera leaves inhibits alcohol-induced steatohepatitis via reducing hepatic lipid accumulation and anti-inflammation in C57BL/6J mice
WO2010054470A1 (fr) Composition de perte de poids de potiron et de fruit du rosier
US20100203117A1 (en) Anti-adipogenic compositions containing piper betle and dolichos biflorus
Chen et al. Polyphenol-rich extracts from Oiltea camellia prevent weight gain in obese mice fed a high-fat diet and slowed the accumulation of triacylglycerols in 3T3-L1 adipocytes
US10624942B2 (en) Composition for amelioration of peri- and post-menopausal symptoms and a process for producing the same
Kim et al. Perilla leaf extract ameliorates obesity and dyslipidemia induced by high‐fat diet
WO2015198346A1 (fr) Composition comprenant un extrait d'alangium salvifolium à activité anti-adipogène ou anti-obésité
Zheng et al. Synergistic action of Erigeron annuus L. Pers and Borago officinalis L. enhances anti-obesity activity in a mouse model of diet-induced obesity
Behrouj et al. Therapeutic effect of Silybum marianum plant extract on tamoxifen-induced fatty liver in rats
Zeitoun et al. Impact of the aqueous extract of dandelion, probiotic and their synbiotic on male lamb’s testicular histopathology relative to semen characteristics
KR101534142B1 (ko) 혼합 생약 추출물을 이용한 대사성질환 예방 및 치료용 조성물
US20180193401A1 (en) Anti-obesity composition comprising natural complex
TWI530293B (zh) 一種荷葉萃取物用於製備預防或治療酒精性肝炎病變之醫藥組合物的用途
Chaudhary et al. Anti-hyperlipidemic and fat pad lowering effect of standardized tea seed cake extract in mice fed high-fat and high-carbohydrate diet
El-Ziney et al. Protective effects of green tea and moringa leave extracts and their bio-yogurts against oxidative effects of lead acetate in albino rats
Mwale et al. Toxicological studies on the leaf extract of Aloe ferox Mill.(Aloaceae)
A Ghaffar et al. Effect of Horsetail (Equisetum arvense) and Hollyhock (Alcea rosea) Leaves in Treatment of Kidney Functions Defects in Gentamicin-Induced Rats
KR20130127088A (ko) 택사 추출물을 함유하는 고지혈증 또는 동맥경화증의 치료 및 예방용 조성물
Shelbaya Effect of ginseng (panax ginseng) against testicular toxicity induced by sodium valproate in male rats
KR102571313B1 (ko) 삼백초추출물과 녹차추출물이 포함된 비만 예방 및 개선용 식품조성물 및 그 제조방법
Vaswani et al. Effect of Tinospora cordifolia as phytogenic feed additive on performance parameters of sahiwal heifers
Uhegbu et al. Some biochemical changes in serum of female albino rats administered aqueous extract of Piper guineense Schumach seeds
ALKATIB Comparison Between effect of Silymarin Extract and Legalon70 in Cyclosporine A-Induced Toxicity in Rats.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09825679

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2743266

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09825679

Country of ref document: EP

Kind code of ref document: A1